Bladder carcinoma (BC) is the most common urinary malignant tumor. In the light of the unsuccessful current therapies and their side effects, new pharmacological strategies are needed. In addition to the well known therapeutic possibilities described in the first section, we focused our attention on very recent and innovative tools to approach this target (new drug candidates from epigenetic modulators to endothelin receptor inhibitors, improved technological formulations, active principles from plants, and dietary components). Then, in the last paragraph, we analyzed the etiology of recurrent BC, with particular attention to cellular microenvironment. In fact, the incidence of recurrence is up to 90%, and 25% of tumours show progression towards invasiveness.

Bladder cancer: Innovative approaches beyond the diagnosis / Piergentili, Roberto; Carradori, Simone; Gulia, Caterina; DE MONTE, Celeste; Cristini, Cristiano; Grande, Pietro; Santini, Edoardo; Gentile, Vincenzo; DI PIERRO, GIOVANNI BATTISTA. - In: CURRENT MEDICINAL CHEMISTRY. - ISSN 0929-8673. - ELETTRONICO. - 21:20(2014), pp. 2219-2236. [10.2174/0929867321666140304110231]

Bladder cancer: Innovative approaches beyond the diagnosis

PIERGENTILI, ROBERTO;CARRADORI, Simone;GULIA, CATERINA;DE MONTE, CELESTE;CRISTINI, Cristiano;GRANDE, PIETRO;SANTINI, EDOARDO;GENTILE, Vincenzo;DI PIERRO, GIOVANNI BATTISTA
2014

Abstract

Bladder carcinoma (BC) is the most common urinary malignant tumor. In the light of the unsuccessful current therapies and their side effects, new pharmacological strategies are needed. In addition to the well known therapeutic possibilities described in the first section, we focused our attention on very recent and innovative tools to approach this target (new drug candidates from epigenetic modulators to endothelin receptor inhibitors, improved technological formulations, active principles from plants, and dietary components). Then, in the last paragraph, we analyzed the etiology of recurrent BC, with particular attention to cellular microenvironment. In fact, the incidence of recurrence is up to 90%, and 25% of tumours show progression towards invasiveness.
bladder cancer; gene therapy; targeted therapy; selective cox-2 inhibitors; peroxisome proliferator-activated receptor agonists.; plant-derived extracts; endothelin receptors; peroxisome proliferator-activated receptor γ agonists; histone deacetylase inhibitors; "field cancerization" recurrence; “field cancerization” recurrence
01 Pubblicazione su rivista::01a Articolo in rivista
Bladder cancer: Innovative approaches beyond the diagnosis / Piergentili, Roberto; Carradori, Simone; Gulia, Caterina; DE MONTE, Celeste; Cristini, Cristiano; Grande, Pietro; Santini, Edoardo; Gentile, Vincenzo; DI PIERRO, GIOVANNI BATTISTA. - In: CURRENT MEDICINAL CHEMISTRY. - ISSN 0929-8673. - ELETTRONICO. - 21:20(2014), pp. 2219-2236. [10.2174/0929867321666140304110231]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/675812
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 12
  • ???jsp.display-item.citation.isi??? 11
social impact